ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.83 CNY | -0.34% |
|
-3.67% | -17.87% |
| 31/05 | Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 06 June 2024 | CI |
| 06/05 | China Approves Tianyu Pharma's Heart Medication | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9,134 | 17,038 | 16,825 | 8,880 | 7,555 | 6,132 | - |
| Enterprise Value (EV) 1 | 9,134 | 17,038 | 16,825 | 8,880 | 7,555 | 6,132 | 6,132 |
| P/E ratio | 15.6 x | 25.5 x | 81.9 x | -75.1 x | 271 x | 23.5 x | 31.8 x |
| Yield | - | 0.53% | 0.21% | - | 0.23% | 0.62% | 0.45% |
| Capitalization / Revenue | 4.33 x | 6.58 x | 6.61 x | 3.33 x | 2.99 x | 2.1 x | 1.83 x |
| EV / Revenue | 4.33 x | 6.58 x | 6.61 x | 3.33 x | 2.99 x | 2.1 x | 1.83 x |
| EV / EBITDA | 11.5 x | 18.7 x | 38.8 x | 58 x | 20.6 x | 10.3 x | 12 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | 4.48 x | 6.42 x | 4.54 x | 2.54 x | 2.17 x | 1.65 x | 1.59 x |
| Nbr of stocks (in thousands) | 3,28,031 | 3,28,002 | 3,47,977 | 3,47,977 | 3,47,977 | 3,43,927 | - |
| Reference price 2 | 27.84 | 51.94 | 48.35 | 25.52 | 21.71 | 17.83 | 17.83 |
| Announcement Date | 23/04/20 | 19/04/21 | 21/04/22 | 26/04/23 | 25/04/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,111 | 2,587 | 2,545 | 2,667 | 2,527 | 2,920 | 3,345 |
| EBITDA 1 | 792.6 | 912.5 | 434.1 | 153.1 | 366.1 | 595 | 509 |
| EBIT 1 | 688.3 | 775.7 | 240.1 | -101.8 | 70.75 | 306 | 228 |
| Operating Margin | 32.61% | 29.98% | 9.43% | -3.82% | 2.8% | 10.48% | 6.82% |
| Earnings before Tax (EBT) 1 | 684.1 | 768.9 | 218.4 | -110.5 | 71.92 | 307 | 229 |
| Net income 1 | 585.7 | 667.1 | 204.7 | -119 | 27.36 | 264 | 196 |
| Net margin | 27.75% | 25.78% | 8.04% | -4.46% | 1.08% | 9.04% | 5.86% |
| EPS 2 | 1.789 | 2.033 | 0.5900 | -0.3400 | 0.0800 | 0.7600 | 0.5600 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.2778 | 0.1000 | - | 0.0500 | 0.1100 | 0.0800 |
| Announcement Date | 23/04/20 | 19/04/21 | 21/04/22 | 26/04/23 | 25/04/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 68.11 |
| Net margin | - |
| EPS 2 | 0.2000 |
| Dividend per Share | - |
| Announcement Date | 28/08/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 33.7% | 28.5% | 5.65% | -3.29% | 0.78% | 7.3% | 5.1% |
| ROA (Net income/ Total Assets) | - | 17.3% | 3.83% | - | 0.43% | 3.9% | 2.7% |
| Assets 1 | - | 3,865 | 5,345 | - | 6,377 | 6,769 | 7,259 |
| Book Value Per Share 2 | 6.210 | 8.090 | 10.70 | 10.00 | 10.00 | 10.80 | 11.20 |
| Cash Flow per Share 2 | 1.300 | 1.900 | -0.7500 | -0.1400 | -0.1300 | 0.9200 | 0.3500 |
| Capex 1 | 353 | 505 | 736 | 523 | 313 | 103 | 108 |
| Capex / Sales | 16.74% | 19.53% | 28.9% | 19.61% | 12.39% | 3.53% | 3.23% |
| Announcement Date | 23/04/20 | 19/04/21 | 21/04/22 | 26/04/23 | 25/04/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
17.83
CNY
Average target price
22.6
CNY
Spread / Average Target
+26.75%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.87% | 84Cr | |
| +20.20% | 4.38TCr | |
| +28.27% | 2.28TCr | |
| +20.25% | 1.56TCr | |
| +19.35% | 1.43TCr | |
| +54.98% | 1.3TCr | |
| -0.05% | 678.76Cr | |
| -12.16% | 641.27Cr | |
| -8.87% | 572.55Cr | |
| +14.65% | 568.66Cr |
- Stock Market
- Equities
- 300702 Stock
- Financials Zhejiang Tianyu Pharmaceutical Co., Ltd.
